Cartesian Therapeutics (RNAC) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free RNAC Stock Alerts $28.26 +3.69 (+15.02%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26 at 2:52 AM | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Research Coverage Started at MizuhoMay 24, 2024 | msn.comMizuho Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic PositioningMay 24, 2024 | msn.comMizuho starts Cartesian at buy, cites lead drug assetMay 24, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Now Covered by MizuhoMizuho began coverage on shares of Cartesian Therapeutics in a report on Friday. They set a "buy" rating and a $40.00 target price on the stock.May 24, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)May 23, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)HC Wainwright reiterated a "buy" rating and set a $54.00 price objective on shares of Cartesian Therapeutics in a report on Thursday.May 22, 2024 | msn.comCartesian stock climbs 8% on FDA regenerative therapy designationMay 22, 2024 | markets.businessinsider.comCartesian: FDA Grants Regenerative Medicine Advanced Therapy Designation For Descartes-08May 22, 2024 | globenewswire.comCartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia GravisMay 17, 2024 | edition.cnn.comCartesian Therapeutics, Inc.May 15, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Short Interest UpdateCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 784,200 shares, an increase of 22.8% from the April 15th total of 638,500 shares. Based on an average daily volume of 62,200 shares, the days-to-cover ratio is currently 12.6 days. Approximately 6.1% of the shares of the company are short sold.May 13, 2024 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 13, 2024 | benzinga.comWhat Makes Cartesian Therapeutics, Inc. a New Buy StockMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic ExpansionMay 10, 2024 | finance.yahoo.comCartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...May 10, 2024 | marketbeat.comCartesian Therapeutics, Inc. to Post FY2028 Earnings of ($7.41) Per Share, Leerink Partnrs Forecasts (NASDAQ:RNAC)Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Leerink Partnrs issued their FY2028 earnings per share (EPS) estimates for Cartesian Therapeutics in a research report issued on Wednesday, May 8th. Leerink Partnrs analyst T. Smith forecasts that the company will earn (May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cartesian Therapeutics with Promising Descartes-08 Therapy Outlook and Strong FinancialsMay 9, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and set a $54.00 price objective on shares of Cartesian Therapeutics in a research note on Thursday.May 9, 2024 | finance.yahoo.comCartesian Therapeutics Reports First Quarter 2024 EarningsMay 8, 2024 | msn.comCartesian Therapeutics GAAP EPS of -$10.50, revenue of $5.84MMay 8, 2024 | investorplace.comRNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a research report on Wednesday.May 8, 2024 | finanznachrichten.deCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comCartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | businesswire.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 25, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) to Post Q1 2024 Earnings of ($0.27) Per Share, HC Wainwright ForecastsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at HC Wainwright upped their Q1 2024 earnings per share estimates for Cartesian Therapeutics in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor now anticipates that the company will pApril 24, 2024 | marketbeat.comFY2027 Earnings Forecast for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC)Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith foApril 24, 2024 | marketbeat.comLeerink Partnrs Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)Leerink Partnrs reaffirmed an "outperform" rating on shares of Cartesian Therapeutics in a report on Tuesday.April 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics: Promising CAR-T Therapy and Strategic Financial MovesApril 23, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Price Target Raised to $54.00 at HC WainwrightHC Wainwright increased their price target on Cartesian Therapeutics from $2.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday.April 22, 2024 | businesswire.comCartesian Therapeutics to Present at the ASGCT 27th Annual MeetingApril 15, 2024 | msn.comMarinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare moversApril 5, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Sets New 1-Year Low at $13.19Cartesian Therapeutics (NASDAQ:RNAC) Reaches New 1-Year Low at $13.19April 5, 2024 | marketbeat.comTrading was temporarily halted for "RNAC" at 07:04 PM with a stated reason of "News pending."April 4, 2024 | businesswire.comCartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | businesswire.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 1, 2024 | marketbeat.comShort Interest in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Expands By 27.3%Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 8,300,000 shares, a growth of 27.3% from the February 29th total of 6,520,000 shares. Based on an average trading volume of 692,200 shares, the short-interest ratio is presently 12.0 days. Currently, 7.8% of the company's stock are sold short.March 28, 2024 | globenewswire.comCartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock SplitMarch 21, 2024 | insidertrades.comInsider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys 19,044 Shares of StockMarch 21, 2024 | finance.yahoo.comCartesian Therapeutics Director Acquires 3.2% More StockMarch 20, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys $11,426.40 in StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) Director Timothy A. Springer acquired 19,044 shares of the company's stock in a transaction on Monday, March 18th. The stock was bought at an average price of $0.60 per share, for a total transaction of $11,426.40. Following the purchase, the director now owns 31,073,406 shares in the company, valued at approximately $18,644,043.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 19, 2024 | insidertrades.comTimothy A. Springer Purchases 648,372 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) StockMarch 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics: Neutral Impact of Xork Termination and High Hopes for Descartes-08 TrialMarch 18, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Timothy A. Springer Purchases 648,372 SharesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) Director Timothy A. Springer bought 648,372 shares of the business's stock in a transaction on Thursday, March 14th. The shares were acquired at an average cost of $0.54 per share, for a total transaction of $350,120.88. Following the purchase, the director now directly owns 30,516,862 shares in the company, valued at $16,479,105.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amidst Strong Financial Position and Promising Descartes-08 Clinical TrialsMarch 7, 2024 | finanznachrichten.deCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 7, 2024 | globenewswire.comCartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | finanznachrichten.deCartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement GrantMarch 6, 2024 | bizjournals.comBiotech moving HQ outside of Montgomery County following merger Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. RNAC Media Mentions By Week RNAC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAC News Sentiment▼0.450.81▲Average Medical News Sentiment RNAC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAC Articles This Week▼153▲RNAC Articles Average Week Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RPTX News Today SYRS News Today FGEN News Today SCPH News Today CTMX News Today ALLK News Today OPTN News Today KPTI News Today MCRB News Today ACET News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAC) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
